Newron's Evenamide Faces FDA Hiccup as Global Schizophrenia Trials Advance on Fresh Funding

FDA freezes US enrolment in Newron's evenamide trial after unrelated death. Global studies continue; strong IP, €38M capital raised. Analysts target CHF 47. Data due Q4 2026.

Newron Pharmaceuticals has entered a tense waiting period. A sudden death in a clinical study outside the United States prompted the FDA to freeze new patient enrolment at American sites for the company's pivotal phase III trial, ENIGMA-TRS 2. Yet the global machinery of the evenamide development program continues to turn, and the balance sheet has been reinforced with fresh capital.

The patient who died was being treated at a non-US centre. Both the investigator and the independent safety committee classified the event as unrelated to evenamide. Newron’s chief medical officer, Ravi Anand, noted that sudden deaths are unfortunately not uncommon in schizophrenia populations, adding that the evenamide programme has not shown an elevated mortality risk versus placebo. The company is now assembling the data the FDA has requested, aiming to lift the clinical hold as quickly as possible.

The freeze remains geographically contained. The parallel study, ENIGMA-TRS 1, is running unaltered across 21 countries and has already enrolled more than 400 patients. ENIGMA-TRS 2, meanwhile, has received regulatory approval in Argentina and India, with Colombia and Malaysia close behind. That regional diversification is deliberate. Newron has licensed Japanese rights to EA Pharma, part of the Eisai group, which launched its own phase III trial at the start of the year. In South Korea, Myung In Pharm has secured development and marketing rights. The strategy reduces the group's reliance on Western study centres.

A structural pillar for the long-term outlook is the strengthened intellectual property position. Newron has secured a new composition-of-matter patent covering crystalline forms of evenamide, extending protection to 2044. National phase patent applications have been filed across all key markets.

On the financing side, Newron is better placed than many early-stage biotechs. In February 2026 the company raised up to €38 million via a capital increase from existing and new European and Asian investors. A further €11 million is contingent on study progress, and an additional €12 million will be triggered if the ENIGMA data are positive. That cash cushion matters because the share price has taken a beating. The stock closed at €15.70 on Friday, down roughly 41% year to date and 52% below its January peak of €32.95. The annualised volatility of nearly 75% reflects the market's jitters.

Analysts remain broadly constructive despite the setback. H.C. Wainwright trimmed its price target from CHF 48 to CHF 44, reversing a March upgrade that followed the 2025 annual results. The consensus target still stands at CHF 47, with three analysts rating the stock a buy and none recommending a sale. The real catalyst, however, lies ahead. Top-line efficacy data from both ENIGMA studies are expected in the fourth quarter of 2026. Before that, the market will watch for three concrete developments: the FDA's response to Newron's data submission, the pace of recruitment in ENIGMA-TRS 1, and any partnership discussions at the BIO Convention in San Diego from June 22 to 25. Each event carries the potential to swing a stock that is already pricing in considerable uncertainty.